The Effect Of Oral Ibandronate In Male Osteoporosis
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Male osteoporosis is a common and important clinical problem, associated with significant
morbidity, mortality and societal expense. Approximately 10% of men =65 years of age are
osteoporotic. The proposed study will evaluate efficacy and safety of oral ibandronate given
150 mg once-monthly for 12 months versus placebo in men with primary osteoporosis. Less
frequent, once monthly, dosing is expected to improve patient's treatment adherence compared
to a weekly dosing regimen.